These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

508 related articles for article (PubMed ID: 31243259)

  • 61. Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologics' register GISEA.
    Iannone F; Ferraccioli G; Sinigaglia L; Favalli EG; Sarzi-Puttini P; Atzeni F; Gorla R; Bazzani C; Govoni M; Farina I; Gremese E; Carletto A; Giollo A; Galeazzi M; Foti R; Bianchino L; La Grasta L; Lapadula G
    Clin Rheumatol; 2018 Feb; 37(2):315-321. PubMed ID: 28980085
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Long-term effectiveness of tocilizumab in patients with rheumatoid arthritis, stratified by number of previous treatment failures with biologic agents: results from the German RABBIT cohort.
    Baganz L; Richter A; Kekow J; Bussmann A; Krause A; Stille C; Listing J; Zink A; Strangfeld A
    Rheumatol Int; 2018 Apr; 38(4):579-587. PubMed ID: 29143933
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study.
    Ljung L; Askling J; Rantapää-Dahlqvist S; Jacobsson L;
    Arthritis Res Ther; 2014 Jun; 16(3):R127. PubMed ID: 24941916
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Comparative effect of tumour necrosis factor inhibitors versus other biological agents on cardiovascular risk-associated biomarkers in patients with rheumatoid arthritis.
    Virone A; Bastard JP; Fellahi S; Capeau J; Rouanet S; Sibilia J; Ravaud P; Berenbaum F; Gottenberg JE; Sellam J
    RMD Open; 2019; 5(2):e000897. PubMed ID: 31413865
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Retention rates of adalimumab, etanercept and infliximab as first and second-line biotherapy in patients with rheumatoid arthritis in daily practice.
    Frazier-Mironer A; Dougados M; Mariette X; Cantagrel A; Deschamps V; Flipo RM; Logeart I; Schaeverbeke T; Sibilia J; Le Loët X; Combe B
    Joint Bone Spine; 2014 Jul; 81(4):352-9. PubMed ID: 24721422
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Outcomes of tumor necrosis factor inhibitor cycling versus switching to a disease-modifying anti-rheumatic drug with a new mechanism of action among patients with rheumatoid arthritis.
    Chastek B; Becker LK; Chen CI; Mahajan P; Curtis JR
    J Med Econ; 2017 May; 20(5):464-473. PubMed ID: 28010149
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules.
    Sakai R; Tanaka M; Nanki T; Watanabe K; Yamazaki H; Koike R; Nagasawa H; Amano K; Saito K; Tanaka Y; Ito S; Sumida T; Ihata A; Ishigatsubo Y; Atsumi T; Koike T; Nakajima A; Tamura N; Fujii T; Dobashi H; Tohma S; Sugihara T; Ueki Y; Hashiramoto A; Kawakami A; Hagino N; Miyasaka N; Harigai M;
    Ann Rheum Dis; 2012 Nov; 71(11):1820-6. PubMed ID: 22504558
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment-results from 12 countries in EuroSpA.
    Brahe CH; Ørnbjerg LM; Jacobsson L; Nissen MJ; Kristianslund EK; Mann H; Santos MJ; Reino JG; Nordström D; Rotar Z; Gudbjornsson B; Onen F; Codreanu C; Lindström U; Möller B; Kvien TK; Pavelka K; Barcelos A; Sánchez-Piedra C; Eklund KK; Tomšič M; Love TJ; Can G; Ionescu R; Loft AG; van der Horst-Bruinsma IE; Macfarlane GJ; Iannone F; Hyldstrup LH; Krogh NS; Østergaard M; Hetland ML
    Rheumatology (Oxford); 2020 Jul; 59(7):1640-1650. PubMed ID: 31665497
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Prevalence and predictors of tumour necrosis factor inhibitor persistence in psoriatic arthritis.
    Stober C; Ye W; Guruparan T; Htut E; Clunie G; Jadon D
    Rheumatology (Oxford); 2018 Jan; 57(1):158-163. PubMed ID: 29077973
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Effects of tumor necrosis factor inhibitors and tocilizumab on the glycosylated hemoglobin levels in patients with rheumatoid arthritis; an observational study.
    Otsuka Y; Kiyohara C; Kashiwado Y; Sawabe T; Nagano S; Kimoto Y; Ayano M; Mitoma H; Akahoshi M; Arinobu Y; Niiro H; Akashi K; Horiuchi T
    PLoS One; 2018; 13(4):e0196368. PubMed ID: 29694426
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Two-year efficacy of tocilizumab in patients with active rheumatoid arthritis in clinical practice.
    Notario Ferreira I; Ferrer González MA; Morales Garrido P; González Utrilla A; García Sanchez A; Soto Pino MJ; Suero Rosario E; Caro Hernández C; Añón Oñate I; Pérez Albaladejo L; Cáliz Cáliz R
    Reumatol Clin; 2017; 13(2):78-84. PubMed ID: 27174398
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR Study.
    Gomez-Reino JJ; Maneiro JR; Ruiz J; Roselló R; Sanmarti R; Romero AB;
    Ann Rheum Dis; 2012 Nov; 71(11):1861-4. PubMed ID: 22736086
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Effects of DMARDs on citrullinated peptide autoantibody levels in RA patients-A longitudinal analysis.
    Wunderlich C; Oliviera I; Figueiredo CP; Rech J; Schett G
    Semin Arthritis Rheum; 2017 Jun; 46(6):709-714. PubMed ID: 28109618
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Comparison of the drug retention and reasons for discontinuation of tumor necrosis factor inhibitors and interleukin-6 inhibitors in Japanese patients with elderly-onset rheumatoid arthritis-the ANSWER cohort study.
    Jinno S; Onishi A; Dubreuil M; Hashimoto M; Yamamoto W; Murata K; Takeuchi T; Kotani T; Maeda Y; Ebina K; Son Y; Amuro H; Hara R; Katayama M; Saegusa J
    Arthritis Res Ther; 2021 Apr; 23(1):116. PubMed ID: 33858490
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort.
    Micheroli R; Tellenbach C; Scherer A; Bürki K; Niederman K; Nissen MJ; Zufferey P; Exer P; Möller B; Kyburz D; Ciurea A
    Ann Rheum Dis; 2020 Sep; 79(9):1203-1209. PubMed ID: 32581090
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Predictive factors for effective selection of Interleukin-6 inhibitor and tumor necrosis factor inhibitor in the treatment of rheumatoid arthritis.
    Hayashi S; Matsubara T; Fukuda K; Funahashi K; Hashimoto M; Maeda T; Kamenaga T; Takashima Y; Matsumoto T; Niikura T; Kuroda R
    Sci Rep; 2020 Oct; 10(1):16645. PubMed ID: 33024253
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Body mass index and treatment survival in patients with RA starting treatment with TNFα-inhibitors: long-term follow-up in the real-life METEOR registry.
    Bergstra SA; Allaart CF; Vega-Morales D; De Buck M; Murphy E; Salomon Escoto K; Huizinga TWJ
    RMD Open; 2020 Jun; 6(2):. PubMed ID: 32506054
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
    Li N; Betts KA; Messali AJ; Skup M; Garg V
    Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study.
    Hyrich KL; Lunt M; Watson KD; Symmons DP; Silman AJ;
    Arthritis Rheum; 2007 Jan; 56(1):13-20. PubMed ID: 17195186
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Agranulocytosis under biotherapy in rheumatoid arthritis: three cases hypothesis of parvovirus B19 involvement in agranulocytosis observed under tocilizumab and rituximab for the treatment of rheumatoid arthritis.
    Giraud C; Tatar Z; Soubrier M
    Clin Rheumatol; 2016 Oct; 35(10):2615-8. PubMed ID: 27541023
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.